Katarzyna K.
- Country
- Poland
- Department
- PL10008: Rheumatology
Research Overview
- Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Evaluation of GSK4527363 in Systemic Lupus Erythematosus and Healthy Participants, Including Chinese and Japanese Cohorts
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
Data & Insights
Has run more than one trial at 314 of 522 partner sites.
Specializations
Autoimmune Disorders
The investigator specializes in treating complex autoimmune conditions, with particular emphasis on systemic lupus erythematosus and Sjögren's syndrome.
- Lupus treatments using novel biologics
- Sjögren's disease interventions
- Systemic autoimmune manifestations
Current research involves evaluating innovative therapeutic approaches for managing severe manifestations of these conditions.
Rheumatologic Conditions
Focuses on advancing treatment options for inflammatory joint disorders, particularly psoriatic arthritis and rheumatoid arthritis.
- Novel biologics for psoriatic arthritis
- Targeted therapies for arthritis
- Treatment-resistant arthritis approaches
Investigates both conventional and innovative therapeutic approaches for inflammatory joint conditions.
Neurological Disorders
Conducts research in neurological autoimmune conditions, including multiple sclerosis and myasthenia gravis.
- Relapsing-remitting multiple sclerosis treatment
- Generalized myasthenia gravis therapies
- Neurological autoimmune interventions
Explores therapeutic approaches for managing complex neurological autoimmune disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.